Pre-clinical efficacy of PU-H71, a novel HSP90 inhibitor, alone and in combination with bortezomib in Ewing sarcoma. - Wikidata - wikimedia - TriplyDB

Pre-clinical efficacy of PU-H71, a novel HSP90 inhibitor, alone and in combination with bortezomib in Ewing sarcoma.

Pre-clinical efficacy of PU-H71, a novel HSP90 inhibitor, alone and in combination with bortezomib in Ewing sarcoma.

http://www.wikidata.org/entity/Q37695872

about

Hsp90: A New Player in DNA Repair?Gene Expression Analysis of the 26S Proteasome Subunit PSMB4 Reveals Significant Upregulation, Different Expression and Association with Proliferation in Human Pulmonary Neuroendocrine Tumours Generation of novel patient-derived CIC- DUX4 sarcoma xenografts and cell lines.Molecular dissection of the mechanism by which EWS/FLI expression compromises actin cytoskeletal integrity and cell adhesion in Ewing sarcoma.The novel HSP90 inhibitor AT13387 potentiates radiation effects in squamous cell carcinoma and adenocarcinoma cells.Radiosynthesis of the iodine-124 labeled Hsp90 inhibitor PU-H71.Targeted polytherapy in small cell sarcoma and its association with doxorubicin.BO-1055, a novel DNA cross-linking agent with remarkable low myelotoxicity shows potent activity in sarcoma models.HSP27 is a partner of JAK2-STAT5 and a potential therapeutic target in myelofibrosis.Novel strategies for targeting leukemia stem cells: sounding the death knell for blood cancer.Adapting to stress - chaperome networks in cancer.

P2860

Q26778944-C5F3DC8D-9C3F-4BE1-8268-C44E6A0FE17C Q28246704-D1E357B2-403B-4C76-A565-700A0390D932 Q33875284-1072E706-6B0F-427A-9E5B-AD31B9869879 Q34166817-AD292B5D-9107-476A-80DB-6E4EE1B9499B Q36546425-2EB78D69-8258-4AD4-B770-4D50DF3D28B6 Q36654876-FF519176-3C8F-4FB2-9041-6513032DEF46 Q38977714-4359244B-0BF2-4B4F-B013-D2366771A2CB Q39985326-12C704A8-48E6-4ABA-89F4-9D3DF9F3228B Q52590991-B00FED6F-BCC8-48A0-BEE6-9E2ACCF662B6 Q52846906-FE1349DD-8553-467E-9D1C-2B0264898F1F Q54425017-CBB31D37-DE48-4639-8A9C-9ACE7F2A4C01

P2860

Pre-clinical efficacy of PU-H71, a novel HSP90 inhibitor, alone and in combination with bortezomib in Ewing sarcoma.

http://www.wikidata.org/entity/Q37695872

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 15 December 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Pre-clinical efficacy of PU-H7 ...... h bortezomib in Ewing sarcoma.

@en

Pre-clinical efficacy of PU-H7 ...... h bortezomib in Ewing sarcoma.

@nl

type

label

Pre-clinical efficacy of PU-H7 ...... h bortezomib in Ewing sarcoma.

@en

Pre-clinical efficacy of PU-H7 ...... h bortezomib in Ewing sarcoma.

@nl

prefLabel

Pre-clinical efficacy of PU-H7 ...... h bortezomib in Ewing sarcoma.

@en

Pre-clinical efficacy of PU-H7 ...... h bortezomib in Ewing sarcoma.

@nl

P1433

Q37695872-749E60C5-5970-46E1-BF3D-BCBDFD60F9C2

P1476

Q37695872-45FD3745-F2F3-49D1-A546-2E798D12065E

P2093

Q37695872-073EBC62-62F9-466E-B467-4EA59414CA60

Q37695872-19EE001B-3E0E-4634-A1F1-0E7267A921A1

Q37695872-56EB09C7-F753-4D9D-90B5-17756E8383A1

Q37695872-7F891382-0960-4098-9AEF-4DD8E65AFD96

Q37695872-8FDADA90-C1B5-4A4B-B4E5-DC04DF70F2E7

Q37695872-96AD833D-BEC1-4F84-B2BF-8C788E372154

Q37695872-9BBAE51C-427D-4792-B6F2-5D5111785293

Q37695872-B5377D26-FCA3-4F98-B500-9F65A18DA9CB

Q37695872-EEB0CB74-945A-4BA5-A3F6-69486A53E415

Q37695872-F6626D5C-076B-4CAC-9A59-80C806F263AD

P2860

Q37695872-0E03573F-19DD-47BF-9ED7-2D7289B20F5A

Q37695872-0FE68F6B-FB71-4794-937C-B8AA52EDBA6E

Q37695872-1A353FC0-3815-462F-8A3B-AA204FF858A0

Q37695872-249F86E1-791E-4B03-B0D8-1583C60D91B6

Q37695872-26C54768-FF49-43E3-B71C-822D32F45E77

Q37695872-329DF231-6617-4ACC-9B7A-12FC16844D14

Q37695872-4A1482CA-6DCC-45A7-AECF-ABDA50CD111F

Q37695872-4A89749B-7E35-4B85-8B5E-0ECAFB872AE9

Q37695872-526AC117-3A12-45FD-AC71-072FF22DCFDA

Q37695872-575D4665-BAB5-41D6-B256-4952D1CA492D

P304

Q37695872-74CD69FA-B545-400C-B9BB-08EEC4F48466

P31

Q37695872-5CE37615-9FB4-4CEB-8318-87B1DFCA6A8B

P356

Q37695872-596C9758-6513-4833-9369-82EA04EF6C19

P433

Q37695872-10760E94-9241-4545-9665-0983B96126E9

P478

Q37695872-657E481C-5E1F-4839-A727-583F3FC96351

P50

Q37695872-ECDB5CA5-FC22-4FFF-8727-50918F6C443F

P577

Q37695872-157E554B-CEAF-45AB-A298-86B99D6743D9

P698

Q37695872-D94DB41E-926A-4E93-8D34-EAA3AFABEA39

P932

Q37695872-D70DDABD-3A46-40C6-93B6-06ACB2084184

P356

J.MOLONC.2013.12.005

P1433

Molecular Oncology

P1476

Pre-clinical efficacy of PU-H7 ...... h bortezomib in Ewing sarcoma.

@en

P2093

Ahmet Zehir

http://www.w3.org/2001/XMLSchema#string

Andre L Moreira

http://www.w3.org/2001/XMLSchema#string

Eloisi Caldas Lopes

http://www.w3.org/2001/XMLSchema#string

Kohji Kosugi

http://www.w3.org/2001/XMLSchema#string

Malcolm A S Moore

http://www.w3.org/2001/XMLSchema#string

Paul A Meyers

http://www.w3.org/2001/XMLSchema#string

Smit K Shah

http://www.w3.org/2001/XMLSchema#string

Srikanth R Ambati

http://www.w3.org/2001/XMLSchema#string

Tony Taldone

http://www.w3.org/2001/XMLSchema#string

Ullas Mony

http://www.w3.org/2001/XMLSchema#string

P2860

Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90

Drug combination studies and their synergy quantification using the Chou-Talalay method

HSP90 and the chaperoning of cancer

Opposite effects of the Hsp90 inhibitor Geldanamycin: induction of apoptosis in PC12, and differentiation in N2A cells.

Dead cell discrimination with 7-amino-actinomycin D in combination with dual color immunofluorescence in single laser flow cytometry.

R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study

A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas.

EWS/FLI1 oncogene activates caspase 3 transcription and triggers apoptosis in vivo.

Outcomes for children and adolescents with cancer: challenges for the twenty-first century.

HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans

P304

323-336

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.MOLONC.2013.12.005

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Gabriela Chiosis

P577

2013-12-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24388362

http://www.w3.org/2001/XMLSchema#string

P932

3982393

http://www.w3.org/2001/XMLSchema#string